<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">36750960</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1752-1947</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>08</Day></PubDate></JournalIssue><Title>Journal of medical case reports</Title><ISOAbbreviation>J Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature.</ArticleTitle><Pagination><StartPage>38</StartPage><MedlinePgn>38</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">38</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13256-023-03762-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura are both causes of thrombocytopenia. Recognizing thrombotic thrombocytopenic purpura is crucial for subsequent treatment and prognosis. In clinical practice, corticosteroids and rituximab can be used to treat both immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura; plasma exchange therapy is the first-line treatment in thrombotic thrombocytopenic purpura, while corticosteroids are strongly recommended as first-line treatment in immune thrombocytopenic purpura. The differential diagnosis of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura is essential in clinical practice. However, case reports have suggested that immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura can occur concurrently.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We report the case of a 32-year-old Asian female without previous disease who presented with pancytopenia, concurrent with immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura. The morphology of the megakaryocytes in the bone marrow indicated immune-mediated thrombocytopenia. The patient received glucocorticoid treatment, and her platelet count increased; however, schistocytes remained high during the course of the therapy. Further investigations revealed ADAMTS13 activity deficiency and positive ADAMTS13 antibodies. The high titer of antinuclear antibody and positive anti-U1-ribonucleoprotein/Smith antibody indicated a potential autoimmune disease. However, the patient did not fulfill the current criteria for systemic lupus erythematosus or mixed connective tissue disease. The patient responded well to plasma exchange therapy, and her platelet count remained normal on further follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura is rare, but clinicians should be aware of this entity to ensure prompt medical intervention. Most of the reported cases involve young women. Human immunodeficiency virus infection, pregnancy, and autoimmune disease are the most common underlying conditions.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hung-Chen</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jinxiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Li-Jun</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Xiao-Wu</ForeName><Initials>XW</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jian-Cheng</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiao-Yan</ForeName><Initials>XY</Initials><Identifier Source="ORCID">0000-0002-7959-423X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. huangxy@hku-szh.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China. huangxy@hku-szh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Case Rep</MedlineTA><NlmUniqueID>101293382</NlmUniqueID><ISSNLinking>1752-1947</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011697" MajorTopicYN="Y">Purpura, Thrombotic Thrombocytopenic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010976" MajorTopicYN="N">Platelet Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Immune thrombocytopenia purpura</Keyword><Keyword MajorTopicYN="N">Thrombotic thrombocytopenia purpura</Keyword><Keyword MajorTopicYN="N">Vaccine-induced thrombotic thrombocytopenia</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>0</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36750960</ArticleId><ArticleId IdType="pmc">PMC9905008</ArticleId><ArticleId IdType="doi">10.1186/s13256-023-03762-y</ArticleId><ArticleId IdType="pii">10.1186/s13256-023-03762-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386&#x2013;2393. doi: 10.1182/blood-2008-07-162503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-07-162503</ArticleId><ArticleId IdType="pubmed">19005182</ArticleId></ArticleIdList></Reference><Reference><Citation>Audia S, Mah&#xe9;vas M, Samson M, et al. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620&#x2013;632. doi: 10.1016/j.autrev.2017.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2017.04.012</ArticleId><ArticleId IdType="pubmed">28428120</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology. 2018;2018(1):530&#x2013;538. doi: 10.1182/asheducation-2018.1.530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/asheducation-2018.1.530</ArticleId><ArticleId IdType="pmc">PMC6246034</ArticleId><ArticleId IdType="pubmed">30504354</ArticleId></ArticleIdList></Reference><Reference><Citation>Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836&#x2013;2846. doi: 10.1182/blood-2016-10-709857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-10-709857</ArticleId><ArticleId IdType="pubmed">28416507</ArticleId></ArticleIdList></Reference><Reference><Citation>Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190&#x2013;4207. doi: 10.1182/blood-2010-08-302984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-08-302984</ArticleId><ArticleId IdType="pubmed">21325604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860&#x2013;3867. doi: 10.1182/blood-2014-11-551580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-11-551580</ArticleId><ArticleId IdType="pmc">PMC4473115</ArticleId><ArticleId IdType="pubmed">25784681</ArticleId></ArticleIdList></Reference><Reference><Citation>Yospur LS, Sun NC, Figueroa P, et al. Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an HIV-positive patient: case report and review of the literature. Am J Hematol. 1996;51(1):73&#x2013;78. doi: 10.1002/(sici)1096-8652(199601)51:1&lt;73::Aid-ajh12&gt;3.0.Co;2-c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1096-8652(199601)51:1&lt;73::Aid-ajh12&gt;3.0.Co;2-c</ArticleId><ArticleId IdType="pubmed">8571942</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Husban N, Al-Kuran O. Post-partum thrombotic thrombocytopenic purpura (TTP) in a patient with known idiopathic (immune) thrombocytopenic purpura: a case report and review of the literature. J Med Case Rep. 2018;12(1):147. doi: 10.1186/s13256-018-1692-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-018-1692-1</ArticleId><ArticleId IdType="pmc">PMC5984346</ArticleId><ArticleId IdType="pubmed">29855343</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DD, Krenzer JA, Kenkre VP, et al. Sequential immune thrombocytopenia (ITP) and thrombotic thrombocytopenic purpura (TTP) in an elderly male patient with primary Sjogren's syndrome: when in doubt, use the PLASMIC Score. Case Rep Med. 2021;2021:6869342. doi: 10.1155/2021/6869342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6869342</ArticleId><ArticleId IdType="pmc">PMC8651386</ArticleId><ArticleId IdType="pubmed">34887925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157&#x2013;e164. doi: 10.1016/s2352-3026(17)30026-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s2352-3026(17)30026-1</ArticleId><ArticleId IdType="pubmed">28259520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharski LR, Lusted D, Glick JL. Thrombotic thrombocytopenic purpura in a previously splenectomized patient. Am J Med. 1976;60(7):1061&#x2013;1063. doi: 10.1016/0002-9343(76)90581-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9343(76)90581-7</ArticleId><ArticleId IdType="pubmed">937351</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein R, Flexner J. Idiopathic thrombocytopenic purpura during remission of thrombotic thrombocytopenic purpura. South Med J. 1984;77(12):1599&#x2013;1601. doi: 10.1097/00007611-198412000-00034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007611-198412000-00034</ArticleId><ArticleId IdType="pubmed">6542250</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisenberg BR, Robinson WL, Mosley CA, et al. Thrombotic thrombocytopenic purpura in human immunodeficiency (HIV)-seropositive males. Am J Hematol. 1988;27(3):212&#x2013;215. doi: 10.1002/ajh.2830270312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.2830270312</ArticleId><ArticleId IdType="pubmed">3348206</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupsky M, Sarel R, Hurwitz N, et al. Late appearance of thrombotic thrombocytopenic purpura after autoimmune hemolytic anemia and in the course of chronic autoimmune thrombocytopenic purpura: two case reports. Acta Haematol. 1991;85(3):139&#x2013;142. doi: 10.1159/000204876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000204876</ArticleId><ArticleId IdType="pubmed">2042447</ArticleId></ArticleIdList></Reference><Reference><Citation>Routy JP, Beaulieu R, Monte M, et al. Immunologic thrombocytopenia followed by thrombotic thrombocytopenic purpura in two HIV1 patients. Am J Hematol. 1991;38(4):327&#x2013;328. doi: 10.1002/ajh.2830380414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.2830380414</ArticleId><ArticleId IdType="pubmed">1746543</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivaram U, Cash M. Purpura fulminans, metastatic endophthalmitis, and thrombotic thrombocytopenic purpura in an HIV-infected patient. N Y State J Med. 1992;92(7):313&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">1518589</ArticleId></ArticleIdList></Reference><Reference><Citation>Olenich M, Schattner E. Postpartum thrombotic thrombocytopenic purpura (TTP) complicating pregnancy-associated immune thrombocytopenic purpura (ITP) Ann Intern Med. 1994;120(10):845&#x2013;847. doi: 10.7326/0003-4819-120-10-199405150-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-120-10-199405150-00005</ArticleId><ArticleId IdType="pubmed">8154644</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad VK, Kim IK, Farrington K, et al. TTP following ITP in an HIV-positive boy. J Pediatr Hematol Oncol. 1996;18(4):384&#x2013;386. doi: 10.1097/00043426-199611000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00043426-199611000-00010</ArticleId><ArticleId IdType="pubmed">8888747</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron BW, Martin MS, Sucharetza BS, et al. Four patients with both thrombotic thrombocytopenic purpura and autoimmune thrombocytopenic purpura: the concept of a mixed immune thrombocytopenia syndrome and indications for plasma exchange. J Clin Apheresis. 2001;16(4):179&#x2013;185. doi: 10.1002/jca.1031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jca.1031</ArticleId><ArticleId IdType="pubmed">11835414</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayraktar S, Eileen B, Shariatmadar S, et al. Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a patient with metastatic neuroendocrine tumour successfully treated with rituximab-CVP. BMJ Case Rep. 2010 doi: 10.1136/bcr.07.2010.3144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr.07.2010.3144</ArticleId><ArticleId IdType="pmc">PMC3029530</ArticleId><ArticleId IdType="pubmed">22798444</ArticleId></ArticleIdList></Reference><Reference><Citation>Changela A, Jagarlamudi K, Villani G, et al. Thrombotic thrombocytopenic purpura complicating immune thrombocytopenic purpura&#x2014;a case report. Am J Hematol. 2011;86(4):383. doi: 10.1002/ajh.21971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.21971</ArticleId><ArticleId IdType="pubmed">21442646</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhat MH, Kuriakose P, Jawad M, et al. Sequential occurrence of thrombotic thrombocytopenic purpura, essential thrombocythemia, and idiopathic thrombocytopenic purpura in a 42-year-old African&#x2013;American woman: a case report and review of the literature. J Med Case Rep. 2012;6:93. doi: 10.1186/1752-1947-6-93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-1947-6-93</ArticleId><ArticleId IdType="pmc">PMC3341186</ArticleId><ArticleId IdType="pubmed">22472269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge H, Shi Z, Zheng Z, et al. Coexistence of thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an Asian woman: a case report. J Int Med Res. 2022;50(3):3000605221085127. doi: 10.1177/03000605221085127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605221085127</ArticleId><ArticleId IdType="pmc">PMC8973045</ArticleId><ArticleId IdType="pubmed">35352601</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385(18):1680&#x2013;1689. doi: 10.1056/NEJMoa2109908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2109908</ArticleId><ArticleId IdType="pubmed">34379914</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun. 2021;121:102662. doi: 10.1016/j.jaut.2021.102662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102662</ArticleId><ArticleId IdType="pmc">PMC8133385</ArticleId><ArticleId IdType="pubmed">34051613</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Selleng K, Palankar R, et al. Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia. Blood. 2021;138(22):2256&#x2013;2268. doi: 10.1182/blood.2021013231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021013231</ArticleId><ArticleId IdType="pmc">PMC8483989</ArticleId><ArticleId IdType="pubmed">34587242</ArticleId></ArticleIdList></Reference><Reference><Citation>Sz&#xf3;stek-Mioduchowska A, Kordowitzki P. Shedding light on the possible link between ADAMTS13 and vaccine&#x2014;induced thrombotic thrombocytopenia. Cells. 2021;10(10):2785. doi: 10.3390/cells10102785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102785</ArticleId><ArticleId IdType="pmc">PMC8535032</ArticleId><ArticleId IdType="pubmed">34685765</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri A, Kim HJ, Xu Y, et al. Crystal structure and substrate-induced activation of ADAMTS13. Nat Commun. 2019;10(1):3781. doi: 10.1038/s41467-019-11474-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11474-5</ArticleId><ArticleId IdType="pmc">PMC6706451</ArticleId><ArticleId IdType="pubmed">31439947</ArticleId></ArticleIdList></Reference><Reference><Citation>Pishko AM, Cuker A. Thrombosis after vaccination with messenger RNA-1273: is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia syndrome? Ann Intern Med. 2021;174(10):1468&#x2013;1469. doi: 10.7326/m21-2680.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m21-2680</ArticleId><ArticleId IdType="pmc">PMC8251937</ArticleId><ArticleId IdType="pubmed">34181441</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi K, Ali N, Nasir N, et al. VITT with inactivated SARS-CoV-2 vaccine&#x2014;index case. Hum Vaccin Immunother. 2022;18(1):2036556. doi: 10.1080/21645515.2022.2036556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2036556</ArticleId><ArticleId IdType="pmc">PMC9009890</ArticleId><ArticleId IdType="pubmed">35254213</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312&#x2013;322. doi: 10.1111/jth.13571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13571</ArticleId><ArticleId IdType="pubmed">27868334</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496&#x2013;2502. doi: 10.1111/jth.15010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15010</ArticleId><ArticleId IdType="pmc">PMC8091490</ArticleId><ArticleId IdType="pubmed">32914526</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell WR, Braine HG, Ness PM, et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. clinical experience in 108 patients. N Engl J Med. 1991;325(6):398&#x2013;403. doi: 10.1056/nejm199108083250605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199108083250605</ArticleId><ArticleId IdType="pubmed">2062331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataland SR, Kourlas PJ, Yang S, et al. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. Blood Adv. 2017;1(23):2075&#x2013;2082. doi: 10.1182/bloodadvances.2017009308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2017009308</ArticleId><ArticleId IdType="pmc">PMC5728286</ArticleId><ArticleId IdType="pubmed">29296854</ArticleId></ArticleIdList></Reference><Reference><Citation>Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829&#x2013;3866. doi: 10.1182/bloodadvances.2019000966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000966</ArticleId><ArticleId IdType="pmc">PMC6963252</ArticleId><ArticleId IdType="pubmed">31794604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukyurt S, Eskazan AE. Assessment and monitoring of patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP): strategies to improve outcomes. J Blood Med. 2020;11:319&#x2013;326. doi: 10.2147/jbm.S205630.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/jbm.S205630</ArticleId><ArticleId IdType="pmc">PMC7532071</ArticleId><ArticleId IdType="pubmed">33061729</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118(3):757&#x2013;765. doi: 10.1182/blood-2010-11-317859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-11-317859</ArticleId><ArticleId IdType="pubmed">21576702</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511&#x2013;522. doi: 10.1056/NEJMoa1505533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1505533</ArticleId><ArticleId IdType="pubmed">26863353</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>